DNER and cancer: Recently, KRAS mutations were also identified as novel resistance biomarkers for BET inhibitors by the genetic analysis of a large set of ~230 cancer cell lines, spanning both hematological and solid cancers, after treatment with a new BET inhibitor GSK525762 (molibresib) in a Phase 1 clinical trial [59].